GRI Bio, Inc. GRI inventory is buying and selling on Tuesday with a robust session quantity of 6.9 million in comparison with a mean quantity of 17.35K, as per knowledge from Benzinga Professional.
GRI Bio reported interim security outcomes from its ongoing Part 2a research evaluating GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF).
In preliminary medical trials up to now and former medical trials with the oral formulation, GRI-0621 has been proven to enhance fibrosis in a number of illness fashions and enhance liver perform assessments and different markers of irritation and harm in sufferers.
The pre-planned interim evaluation for 2-week security outcomes from the continuing Part 2a biomarker research demonstrated GRI-0621 (4.5mg orally as soon as every day) to be protected and well-tolerated within the first 12 sufferers evaluated per protocol.
Hyperlipidemia (excessive ldl cholesterol) was not seen within the 12 sufferers assessed on the 2-week go to.
There have been no significant modifications in levels of cholesterol in sufferers receiving GRI-0621, and all topics remained inside regular ranges.
The interim evaluation committee beneficial the research ought to proceed as deliberate.
The interim outcomes present that GRI-0621’s receptor selectivity is in step with the toxicity profile noticed in earlier research evaluating oral tazarotene in over 1,700 sufferers handled for as much as 52 weeks.
The corporate expects to report interim biomarker knowledge in Q2 2025. Topline outcomes from the Part 2a biomarker research are anticipated within the third quarter of 2025.
Worth Motion: GRI inventory is up 95.9% at $6.27 on the final verify Tuesday.
Learn Subsequent:
Momentum3.80
Development–
High quality–
Worth–
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
